

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) November 7, 2001  
-----

BECTON, DICKINSON AND COMPANY

-----  
(Exact name of registrant as specified in its charter)

<TABLE>		
<S>	<C>	<C>
New Jersey	001-4802	22-0760120
-----		
(State or other juris- diction of incorporation)	(Commission File Number)	(IRS Employer Iden- tification Number)
1 Becton Drive, Franklin Lakes, New Jersey		07417-1880
-----		
(Address of principal executive offices)		(Zip Code)

Registrant's telephone number, including area code (201) 847-6800  
-----

N/A

-----  
(Former name or former addresses if changed since last report.)

Item 5. OTHER EVENTS

On November 7, 2001 the Registrant announced in a press release its results for the fourth quarter and fiscal year ended September 30, 2001.

A copy of the press release is attached as Exhibit 99.1.

Item 7. Financial Statements. Pro Forma Financial Information and Exhibits.

(c) Exhibits.

Exhibit 99.1 Press release dated November 7, 2001  
announcing the financial results for the fourth quarter and  
fiscal year ended September 30, 2001.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the

undersigned hereunto duly authorized.

BECTON, DICKINSON AND COMPANY  
(Registrant)

By: /s/ Kathleen M. Gibson  
-----  
Kathleen M. Gibson  
Assistant Secretary

Date: November 7, 2001

2

INDEX TO EXHIBITS  
-----

<TABLE>  
<CAPTION>

Exhibit Number -----	Description of Exhibits -----
<S> 99.1	<C> Press release issued November 7, 2001.

</TABLE>

[LOGO]

Contact:  
Dean J. Paranicas/Investor and Media Relations - 201-847-7102

BD ANNOUNCES RECORD FISCAL FOURTH QUARTER REVENUES

Franklin Lakes, NJ (November 7, 2001) - BD (Becton, Dickinson and Company) (NYSE:BDX) today reported record revenues of \$988 million for the fourth quarter ended September 30, 2001. Revenues increased 7 percent over the same period a year ago. At constant foreign exchange rates, revenues increased 10 percent. For the full year, the Company reported revenues of \$3.8 billion, a 4 percent increase over a year ago, or 7 percent at constant foreign exchange rates. Reported revenues and earnings for fiscal 2001 reflect the adoption of the Securities and Exchange Commission (SEC) Staff Accounting Bulletin No. 101 (SAB 101), "Revenue Recognition in Financial Statements." The adoption of SAB 101, which affects the timing of revenue recognition of certain transactions, reduced fourth quarter revenues by about \$8 million, and had a negligible impact on full year revenues.

Diluted earnings per share for the fourth quarter were 49 cents, and \$1.63 for the full year before a 14 cent non-cash cumulative effect adjustment recorded as of the beginning of fiscal 2001, each of which reflect the adoption of SAB 101. On a pre-SAB 101 basis, diluted earnings per share would have been 50 cents for the quarter and \$1.63 for the full year. Additional details describing SAB 101 and its impact on the Company's fiscal 2001 quarterly revenues, net income

and diluted earnings per share, as well as the related cumulative effect adjustment, are provided in a Note to the Consolidated Income Statements included with this press release.

Diluted earnings per share in last year's fourth quarter of 32 cents included special charges associated with a worldwide organizational restructuring and certain estimated litigation costs, gains on investments and a favorable tax effect from the conclusion of certain tax audits. Excluding these items, diluted earnings per share for the fourth quarter of fiscal 2000 would have been 39 cents. Comparative reported diluted earnings per share for fiscal 2000 would have been \$1.49.

"We continue to deliver revenue and earnings growth in line with the commitments we have made to our shareholders," said Edward J. Ludwig, president and chief executive officer. "For the fourth quarter, as well as the year, our performance reflects the success of our key revenue growth drivers: safety-engineered devices, prefillable drug delivery devices and BD Biosciences products. This revenue growth, along with continued control over costs, has resulted in a significant improvement in operating margin and a 12 percent increase in net income before the SAB 101 accounting change in fiscal 2001."

BD Medical Systems

In the BD Medical Systems segment, worldwide revenues of \$537 million increased 7 percent for the quarter, or 10 percent at constant foreign exchange rates. U.S. sales of safety-engineered products were \$78 million in the fourth quarter, an 18 percent increase over the third quarter, and

an 89 percent increase over the prior year's fourth quarter. Sales of safety-engineered products for the full year totaled \$253 million, representing an increase of 55 percent over the prior year. Sales of prefillable drug delivery devices, which grew by 17 percent in the fourth quarter and 10 percent for the full year, also contributed to the overall growth of this segment. Reported segment growth for the quarter and year also benefited from a favorable comparison with the prior year's fourth quarter, which reflected the impact of discontinuing U.S. medical surgical distributor incentives in that quarter. Revenue growth was offset in part by lower recorded sales of diabetes syringes versus the prior year's fourth quarter. This is primarily the result of the Company beginning to redirect promotional efforts toward sustaining its branded syringe sales at the retail level and developing the U.S. pen needle market, as was discussed in the third quarter press release. In addition, the adoption of SAB 101 decreased fourth quarter diabetes syringe revenues by approximately \$5 million.

BD Clinical Laboratory Solutions

In the BD Clinical Laboratory Solutions segment, worldwide revenues of \$295 million increased 10 percent in the fourth quarter, or 12 percent at constant foreign exchange rates. U.S. sales of safety-engineered products were \$50 million in the fourth quarter, a 17 percent increase over the third quarter, and an 84 percent increase over the prior year's fourth quarter. Sales of safety-engineered products for the full year totaled \$163 million, representing an increase of 59 percent over the prior year. Reported segment growth for the quarter also benefited from a favorable comparison with the prior year's fourth quarter, which reflected the impact of discontinuing U.S.

distributor incentives in that quarter. Growth in the segment also reflects increased worldwide sales of its molecular diagnostic platform, BD ProbeTec ET.

#### BD Biosciences

Revenues for the BD Biosciences segment grew 3 percent to \$155 million in the fourth quarter. At constant foreign exchange rates, revenues increased 5 percent. The adoption of SAB 101 reduced the segment's reported fourth quarter revenues by \$3 million. The Company believes that the events of September 11 adversely affected fourth quarter revenues by as much as \$5 million due to disruptions to air shipments and research and business activities at several private and government sector customers. Revenue growth for the year was 8 percent, or 11 percent at constant foreign exchange rates.

#### Geographic Revenues

Fourth quarter revenues in the United States increased 15 percent to \$545 million. Revenues outside the United States of \$442 million were about 1 percent below the prior year, although at constant foreign exchange rates revenues advanced 5 percent. For the full year, revenues in the U.S. increased 8 percent to \$2 billion. Revenues of \$1.7 billion outside the U.S. were about 1 percent below last year on a reported basis, but grew by 7 percent at constant foreign exchange rates.

#### Fiscal 2002 Outlook

The Company expects fiscal 2002 diluted earnings per share growth of approximately 10 percent over comparable fiscal 2001 diluted earnings per share of \$1.63. In addition, the Company will adopt Statement of Financial Accounting Standards (SFAS) No. 142, "Goodwill and Other Intangible Assets," which, among other things, eliminates the requirement to amortize goodwill. The adoption is expected to result in additional earnings per share of approximately 9 cents relating to the elimination of goodwill amortization. The Company announced it also is considering actions to increase operating efficiency. These actions could include a smaller scale restructuring of manufacturing facilities in the BD Medical Systems segment. In addition, the Company is considering the divestiture of some business units with combined revenues of less than \$200 million. Assuming that all of these actions are substantially completed during fiscal 2002, the Company would still expect earnings per share growth of approximately 10 percent, excluding any gains or losses on sales of business units or special charges.

BD is a leading global medical technology company that manufactures and sells a broad range of supplies, devices and systems for use by healthcare professionals, medical research institutions, industry and the general public.

This press release may contain certain forward-looking statements (as defined under Federal securities laws) regarding the Company's performance, including future revenues, products and income, or events or developments that the Company expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of the Company and involve a number of business risks

and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. Factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; uncertainties of litigation; the Company's ability to achieve sales and earnings forecasts, which are based on sales volume and product mix assumptions, to achieve its cost savings objectives, and to achieve anticipated synergies and other cost savings in connection with acquisitions; changes in regional, national or foreign economic conditions; increases in energy costs;

fluctuations in costs and availability of raw materials and in the Company's ability to maintain favorable supplier arrangements and relationships; changes in interest or foreign currency exchange rates; delays in product introductions; and changes in healthcare or other governmental regulation, as well as other factors discussed in this press release and in the Company's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements.

###

BD's news releases can be found on its website [www.bd.com](http://www.bd.com) or through Business Wire at [www.businesswire.com](http://www.businesswire.com). A conference call with analysts regarding this news release will be broadcast live on BD's website at 8:30 a.m. EST Thursday, November 8, 2001, and will be available for replay at [www.bd.com](http://www.bd.com) through November 15, 2001.

<Page>

BECTON DICKINSON AND COMPANY  
CONSOLIDATED INCOME STATEMENTS  
(Unaudited; Amounts in thousands, except per-share data)

<TABLE>  
<CAPTION>

	Three Months Ended September 30,		
	2001	2000	% Change
<S>	<C>	<C>	<C>
REVENUES	\$ 987,525	\$ 919,898	7.4
Cost of products sold	497,745	470,556	5.8
Selling and administrative	257,383	247,228	4.1
Research and development	51,505	52,662	(2.2)
Special charges	-	57,514	NM
TOTAL OPERATING COSTS AND EXPENSES	806,633	827,960	(2.6)
OPERATING INCOME	180,892	91,938	96.8
Interest expense, net	(7,697)	(13,877)	(44.5)
Gains on investments, net	-	11,288	NM
Other income, net	30	2,221	(98.6)
INCOME BEFORE INCOME TAXES	173,225	91,570	89.2
Income tax provision	40,815	7,556	NM
NET INCOME	\$ 132,410	\$ 84,014	57.6
EARNINGS PER SHARE			
Basic	\$ 0.51	\$ 0.33	54.5
Diluted	\$ 0.49	\$ 0.32	53.1
AVERAGE SHARES OUTSTANDING			
Basic	258,952	253,526	
Diluted	270,376	263,848	

</TABLE>

NM - Not Meaningful

All 2001 amounts presented in the Consolidated Income Statements and Supplemental Revenue Information reflect the adoption of Securities and Exchange Commission Staff Accounting Bulletin No. 101 (SAB 101), "Revenue Recognition in Financial Statements." See Note to Consolidated Income Statements which discusses the adoption of SAB 101.

<Page>

BECTON DICKINSON AND COMPANY  
CONSOLIDATED INCOME STATEMENTS  
(Unaudited; Amounts in thousands, except per-share data)

<TABLE>  
<CAPTION>

	Twelve Months Ended September 30,		
	2001	2000	% Change
<S>	<C>	<C>	<C>
REVENUES	\$ 3,754,302	\$ 3,618,334	3.8
Cost of products sold	1,913,292	1,848,332	3.5
Selling and administrative	983,296	973,902	1.0
Research and development	211,834	223,782	(5.3)
Special charges	-	57,514	NM
TOTAL OPERATING COSTS AND EXPENSES	3,108,422	3,103,530	0.2
OPERATING INCOME	645,880	514,804	25.5
Interest expense, net	(55,414)	(74,197)	(25.3)
Gains on investments, net	-	76,213	NM
Other (expense) income, net	(13,716)	3,114	NM
INCOME BEFORE INCOME TAXES	576,750	519,934	10.9
Income tax provision	138,348	127,037	8.9
INCOME BEFORE CUMULATIVE EFFECT OF CHANGE IN ACCOUNTING PRINCIPLE, NET OF TAX	438,402	392,897	11.6
Cumulative effect, net of tax	(36,750)	-	NM
NET INCOME	\$ 401,652	\$ 392,897	NM
BASIC EARNINGS PER SHARE			
Before Cumulative Effect	\$ 1.69	\$ 1.54	9.7
Cumulative Effect	(0.14)	-	NM
Basic Earnings Per Share	\$ 1.55	\$ 1.54	NM
DILUTED EARNINGS PER SHARE			
Before Cumulative Effect	\$ 1.63	\$ 1.49	9.4
Cumulative Effect	(0.14)	-	NM
Diluted Earnings Per Share	\$ 1.49	\$ 1.49	NM
AVERAGE SHARES OUTSTANDING			
Basic	257,128	252,454	
Diluted	268,833	263,239	

</TABLE>

NM - Not Meaningful

See Note to Consolidated Income Statements for discussion on the adoption of SAB 101.

<Page>

BECTON DICKINSON AND COMPANY  
 NOTE TO CONSOLIDATED INCOME STATEMENTS  
 SUMMARY OF ACCOUNTING CHANGE  
 Three Months and Twelve Months Ended September 30, 2001

As required by the SEC, BD adopted SAB No. 101 in the fourth quarter of fiscal 2001, retroactive to October 1, 2000, and has restated its first three quarters of 2001. SAB 101 provides the SEC's views on the timing of revenue recognition for certain transactions for which explicit guidance had not previously been available. The adoption of SAB 101 is not expected to have a material effect on BD's ongoing results.

Upon adoption of SAB 101, revenue from the sale of certain instruments in the Biosciences segment are recognized upon installation at the customer's site, rather than upon shipment. In addition, the Company changed its method of accounting for revenue related to those branded insulin syringe products that are sold under incentive programs to distributors in the U.S. consumer trade channel. The Company concluded that the more preferable method is to defer revenue recognition until such product is sold by the distributor to the end customer.

The adoption of SAB 101 had the effect of including in 2001 revenues, approximately \$80.7 million of revenues and associated net income that had been previously recognized in fiscal 2000. Similarly, approximately \$80.3 million of revenues which, prior to the adoption of SAB 101, would have been included in fiscal 2001 were deferred to 2002. Consequently, the adoption of SAB 101 increased Biosciences revenues for the year by \$3.4 million and decreased Medical Systems' revenues for the year by \$3.1 million. As a result, the adoption of SAB 101 did not have a significant impact on revenues, net income, or earnings per share for the year. In accordance with SAB 101, BD recorded a \$0.14 per share cumulative effect adjustment in fiscal 2001. This adjustment offsets the net income associated with the aforementioned \$80.7 million of revenues that had previously been recorded in fiscal 2000 and therefore already reflected in the Company's retained earnings.

All 2001 amounts presented in the Consolidated Income Statements and Supplemental Revenue Information reflect the adoption of SAB 101. The schedule that follows shows the impact of the adoption of SAB 101 by quarter for fiscal 2001. Also included in this exhibit are the restated results for the first three quarters of fiscal 2001.

<Page>

BECTON DICKINSON AND COMPANY  
 NOTE TO CONSOLIDATED INCOME STATEMENTS  
 FISCAL 2001 IMPACT OF SAB 101 ADOPTION ON REVENUES,  
 BY PRODUCT GROUP AND REGION  
 (Unaudited; Amounts in thousands)

<TABLE>  
 <CAPTION>

	Q1	Q2
	-----	-----
<S>	<C>	<C>
CONSUMER HEALTH CARE		
United States	\$ 23,985	\$ (6,431)
IMMUNOCYTOLOGY & REAGENTS		
United States	3,660	(967)
International	(582)	(614)
-----		
TOTAL IMMUNOCYTOLOGY	3,078	(1,581)
-----		
NET INCREASE (DECREASE)		
TO REVENUES	\$ 27,063	\$ (8,012)
-----		

	Q3	Q4 *
	-----	-----
CONSUMER HEALTH CARE		
United States	\$ (15,679)	\$ (4,933)
IMMUNOCYTOLOGY & REAGENTS		
United States	122	(471)

International	4,655	(2,373)
-----		
TOTAL IMMUNOCYTOmetry	4,777	(2,844)
-----		
NET INCREASE (DECREASE) TO REVENUES	\$ (10,902)	\$ (7,777)
-----		

</TABLE>

\* The Consolidated Income Statement and Supplemental Revenue Information for the fourth quarter reflect the adoption of SAB 101.

Page 4

<Page>

BECTON DICKINSON AND COMPANY  
 RESTATED FIRST QUARTER FISCAL 2001  
 (Unaudited; Amounts in thousands, except per-share data)

<TABLE>  
 <CAPTION>

	Three Months Ended December 31,		
	2000 *	1999	% Change
-----			
<S>	<C>	<C>	<C>
REVENUES	\$ 870,320	\$ 859,164	1.3
Cost of products sold	453,918	449,951	0.9
Selling and administrative	235,292	233,838	0.6
Research and development	52,727	53,743	(1.9)
-----			
TOTAL OPERATING COSTS AND EXPENSES	741,937	737,532	0.6
-----			
OPERATING INCOME	128,383	121,632	5.6
Interest expense, net	(18,564)	(21,557)	(13.9)
Other (expense) income, net	(7,961)	1,674	NM
-----			
INCOME BEFORE INCOME TAXES	101,858	101,749	0.1
Income tax provision	28,160	26,455	6.4
-----			
INCOME BEFORE CUMULATIVE EFFECT OF CHANGE IN ACCOUNTING PRINCIPLE, NET OF TAX	73,698	75,294	(2.1)
Cumulative effect, net of tax	(36,750)	-	NM
-----			
NET INCOME	\$ 36,948	\$ 75,294	NM
-----			
BASIC EARNINGS PER SHARE			
Before Cumulative Effect	\$ 0.29	\$ 0.30	(3.3)
Cumulative Effect	(0.14)	-	NM
-----			
Basic Earnings Per Share	\$ 0.15	\$ 0.30	NM
-----			
DILUTED EARNINGS PER SHARE			
Before Cumulative Effect	\$ 0.28	\$ 0.29	(3.4)
Cumulative Effect	(0.14)	-	NM
-----			
Diluted Earnings Per Share	\$ 0.14	\$ 0.29	NM
-----			

AVERAGE SHARES OUTSTANDING



Basic	254,465	251,328
Diluted	266,237	262,593

</TABLE>

NM - Not Meaningful

\* All 2001 amounts presented reflect the adoption of SAB 101.

Page 5

<Page>

BECTON DICKINSON AND COMPANY  
 RESTATED SECOND QUARTER FISCAL 2001  
 (Unaudited; Amounts in thousands, except per-share data)

<TABLE>  
 <CAPTION>

	Three Months Ended March 31, 2001		
	2001 *	2000	% Change
<S>	<C>	<C>	<C>
REVENUES	\$ 953,167	\$ 925,132	3.0
Cost of products sold	486,738	473,987	2.7
Selling and administrative	241,912	244,063	(0.9)
Research and development	54,497	57,175	(4.7)
TOTAL OPERATING COSTS AND EXPENSES	783,147	775,225	1.0
OPERATING INCOME	170,020	149,907	13.4
Interest expense, net	(15,998)	(21,199)	(24.5)
Other (expense) income, net	(5,418)	36,399	NM
INCOME BEFORE INCOME TAXES	148,604	165,107	(10.0)
Income tax provision	34,439	45,936	(25.0)
NET INCOME	\$ 114,165	\$ 119,171	(4.2)
EARNINGS PER SHARE			
Basic	\$ 0.44	\$ 0.47	(6.4)
Diluted	\$ 0.42	\$ 0.45	(6.7)

AVERAGE SHARES OUTSTANDING

Basic	257,021	252,055
Diluted	269,172	263,376

</TABLE>

NM - Not Meaningful

\* All 2001 amounts presented reflect the adoption of SAB 101.

Page 6

<Page>

BECTON DICKINSON AND COMPANY  
 RESTATED THIRD QUARTER FISCAL 2001  
 (Unaudited; Amounts in thousands, except per-share data)

<TABLE>  
 <CAPTION>

Three Months Ended June 30,

	2001 *	2000	% Change
<S>	<C>	<C>	<C>
REVENUES	\$ 943,290	\$ 914,140	3.2
Cost of products sold	474,891	453,838	4.6
Selling and administrative	248,709	248,773	(0.0)
Research and development	53,105	60,202	(11.8)
TOTAL OPERATING COSTS AND EXPENSES	776,705	762,813	1.8
OPERATING INCOME	166,585	151,327	10.1
Interest expense, net	(13,155)	(17,564)	(25.1)
Gains on investments, net	-	31,766	NM
Other expense, net	(367)	(4,021)	(90.9)
INCOME BEFORE INCOME TAXES	153,063	161,508	(5.2)
Income tax provision	34,934	47,090	(25.8)
NET INCOME	\$ 118,129	\$ 114,418	3.2
EARNINGS PER SHARE			
Basic	\$ 0.46	\$ 0.45	2.2
Diluted	\$ 0.44	\$ 0.43	2.3

AVERAGE SHARES OUTSTANDING

Basic	258,086	252,904
Diluted	269,653	263,659

</TABLE>

NM - Not Meaningful

\* All 2001 amounts presented reflect the adoption of SAB 101.

Page 7

<Page>

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENT AND GEOGRAPHIC AREA  
(Unaudited; Amounts in thousands)

<TABLE>  
<CAPTION>

	Three Months Ended September 30,		
	2001	2000	% Change
<S>	<C>	<C>	<C>
MEDICAL SYSTEMS			
United States	\$ 281,652	\$ 239,323	17.7
International	255,643	262,599	(2.6)
TOTAL	\$ 537,295	\$ 501,922	7.0
CLINICAL LABORATORY SOLUTIONS			
United States	\$ 175,719	\$ 149,517	17.5
International	119,306	118,423	0.7
TOTAL	\$ 295,025	\$ 267,940	10.1
BIOSCIENCES			
United States	\$ 87,878	\$ 85,116	3.2
International	67,327	64,920	3.7
TOTAL	\$ 155,205	\$ 150,036	3.4

TOTAL REVENUES					
United States	\$	545,249	\$	473,956	15.0
International		442,276		445,942	(0.8)
-----					
TOTAL	\$	987,525	\$	919,898	7.4
-----					

<TABLE>  
<CAPTION>

Twelve Months Ended September 30,					
2001                      2000                      % Change					
-----					
<S>	<C>		<C>		<C>
MEDICAL SYSTEMS					
United States	\$	1,007,601	\$	927,355	8.7
International		999,939		1,038,684	(3.7)
-----					
TOTAL	\$	2,007,540	\$	1,966,039	2.1
-----					

CLINICAL LABORATORY SOLUTIONS					
United States	\$	679,880	\$	623,490	9.0
International		474,872		478,862	(0.8)
-----					
TOTAL	\$	1,154,752	\$	1,102,352	4.8
-----					

BIOSCIENCES					
United States	\$	329,042	\$	312,710	5.2
International		262,968		237,233	10.8
-----					
TOTAL	\$	592,010	\$	549,943	7.6
-----					

TOTAL REVENUES					
United States	\$	2,016,523	\$	1,863,555	8.2
International		1,737,779		1,754,779	(1.0)
-----					
TOTAL	\$	3,754,302	\$	3,618,334	3.8
-----					

</TABLE>

Page 8

<Page>

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENT AND MAJOR PRODUCT GROUPS  
Three Months Ended September 30,  
(Unaudited; Amounts in thousands)

<TABLE>  
<CAPTION>

United States					
-----					
2001                      2000                      % Change					
-----					
<S>	<C>		<C>		<C>
MEDICAL SYSTEMS					
Medical Surgical	\$	178,590	\$	122,116	46.2
Consumer Health Care		77,349		96,239	(19.6)
Pharmaceutical Systems		19,142		14,716	30.1
Ophthalmic Systems		6,571		6,252	5.1
-----					
TOTAL	\$	281,652	\$	239,323	17.7
-----					

CLINICAL LABORATORY SOLUTIONS					
Preanalytical Solutions	\$	95,734	\$	71,262	34.3
Diagnostic Systems		79,985		78,255	2.2
-----					
TOTAL	\$	175,719	\$	149,517	17.5
-----					

BIOSCIENCES

Immunocytometry & Reagents	\$	65,019	\$	64,063	1.5
Discovery Labware		22,859		21,053	8.6
-----					
TOTAL	\$	87,878	\$	85,116	3.2
-----					
TOTAL UNITED STATES	\$	545,249	\$	473,956	15.0
-----					

</TABLE>

<TABLE>  
<CAPTION>

International					
-----					
		2001		2000	% Change
-----					
<S>	<C>		<C>		<C>
MEDICAL SYSTEMS					
Medical Surgical	\$	146,435	\$	159,072	(7.9)
Consumer Health Care		44,804		46,667	(4.0)
Pharmaceutical Systems		58,300		51,223	13.8
Ophthalmic Systems		6,104		5,637	8.3
-----					
TOTAL	\$	255,643	\$	262,599	(2.6)
-----					
CLINICAL LABORATORY SOLUTIONS					
Preanalytical Solutions	\$	60,355	\$	59,264	1.8
Diagnostic Systems		58,951		59,159	(0.4)
-----					
TOTAL	\$	119,306	\$	118,423	0.7
-----					
BIOSCIENCES					
Immunocytometry & Reagents	\$	50,988	\$	48,821	4.4
Discovery Labware		16,339		16,099	1.5
-----					
TOTAL	\$	67,327	\$	64,920	3.7
-----					
TOTAL INTERNATIONAL	\$	442,276	\$	445,942	(0.8)
-----					

</TABLE>

Page 9

<Page>

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENT AND MAJOR PRODUCT GROUPS  
Three Months Ended September 30, (continued)  
(Unaudited; Amounts in thousands)

<TABLE>  
<CAPTION>

Total					
-----					
		2001		2000	% Change
-----					
<S>	<C>		<C>		<C>
MEDICAL SYSTEMS					
Medical Surgical	\$	325,025	\$	281,188	15.6
Consumer Health Care		122,153		142,906	(14.5)
Pharmaceutical Systems		77,442		65,939	17.4
Ophthalmic Systems		12,675		11,889	6.6
-----					
TOTAL	\$	537,295	\$	501,922	7.0
-----					
CLINICAL LABORATORY SOLUTIONS					
Preanalytical Solutions	\$	156,089	\$	130,526	19.6
Diagnostic Systems		138,936		137,414	1.1
-----					
TOTAL	\$	295,025	\$	267,940	10.1
-----					
BIOSCIENCES					
Immunocytometry & Reagents	\$	116,007	\$	112,884	2.8
Discovery Labware		39,198		37,152	5.5

TOTAL	\$	155,205	\$	150,036	3.4
TOTAL REVENUES	\$	987,525	\$	919,898	7.4

<TABLE>  
<CAPTION>

	FX Neutral % Growth	
	International	Total
<S>	<C>	<C>
MEDICAL SYSTEMS		
Medical Surgical	(1.2)	19.4
Consumer Health Care	2.0	(12.6)
Pharmaceutical Systems	20.1	22.3
Ophthalmic Systems	12.8	8.7
TOTAL	3.8	10.4
CLINICAL LABORATORY SOLUTIONS		
Preanalytical Solutions	6.5	21.7
Diagnostic Systems	4.8	3.3
TOTAL	5.7	12.3
BIOSCIENCES		
Immunocytometry & Reagents	8.5	4.5
Discovery Labware	7.0	7.9
TOTAL	8.1	5.4
TOTAL	4.9	10.1

</TABLE>

Page 10

<Page>

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENT AND MAJOR PRODUCT GROUPS  
Twelve Months Ended September 30,  
(Unaudited; Amounts in thousands)

<TABLE>  
<CAPTION>

	United States		
	2001	2000	% Change
<S>	<C>	<C>	<C>
MEDICAL SYSTEMS			
Medical Surgical	\$ 630,666	\$ 544,532	15.8
Consumer Health Care	291,371	307,082	(5.1)
Pharmaceutical Systems	57,606	48,140	19.7
Ophthalmic Systems	27,958	27,601	1.3
TOTAL	\$ 1,007,601	\$ 927,355	8.7
CLINICAL LABORATORY SOLUTIONS			
Preanalytical Solutions	\$ 345,699	\$ 291,801	18.5
Diagnostic Systems	334,181	331,689	0.8
TOTAL	\$ 679,880	\$ 623,490	9.0
BIOSCIENCES			
Immunocytometry & Reagents	\$ 239,214	\$ 231,793	3.2
Discovery Labware	89,828	80,917	11.0

TOTAL	\$	329,042	\$	312,710	5.2
-----					
TOTAL UNITED STATES	\$	2,016,523	\$	1,863,555	8.2
-----					
International					
		2001		2000	% Change
-----					
<S>	<C>		<C>		<C>
-----					
MEDICAL SYSTEMS					
Medical Surgical	\$	569,190	\$	612,043	(7.0)
Consumer Health Care		186,093		198,170	(6.1)
Pharmaceutical Systems		221,485		206,681	7.2
Ophthalmic Systems		23,171		21,790	6.3
-----					
TOTAL	\$	999,939	\$	1,038,684	(3.7)
-----					
CLINICAL LABORATORY SOLUTIONS					
Preanalytical Solutions	\$	239,634	\$	242,991	(1.4)
Diagnostic Systems		235,238		235,871	(0.3)
-----					
TOTAL	\$	474,872	\$	478,862	(0.8)
-----					
BIOSCIENCES					
Immunocytometry & Reagents	\$	200,963	\$	174,906	14.9
Discovery Labware		62,005		62,327	(0.5)
-----					
TOTAL	\$	262,968	\$	237,233	10.8
-----					
TOTAL INTERNATIONAL	\$	1,737,779	\$	1,754,779	(1.0)
-----					

Page 11

<Page>

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENT AND MAJOR PRODUCT GROUPS  
Twelve Months Ended September 30, (continued)  
(Unaudited; Amounts in thousands)

Total					
		2001		2000	% Change
-----					
<S>	<C>		<C>		<C>
-----					
MEDICAL SYSTEMS					
Medical Surgical	\$	1,199,856	\$	1,156,575	3.7
Consumer Health Care		477,464		505,252	(5.5)
Pharmaceutical Systems		279,091		254,821	9.5
Ophthalmic Systems		51,129		49,391	3.5
-----					
TOTAL	\$	2,007,540	\$	1,966,039	2.1
-----					
CLINICAL LABORATORY SOLUTIONS					
Preanalytical Solutions	\$	585,333	\$	534,792	9.5
Diagnostic Systems		569,419		567,560	0.3
-----					
TOTAL	\$	1,154,752	\$	1,102,352	4.8
-----					
BIOSCIENCES					
Immunocytometry & Reagents	\$	440,177	\$	406,699	8.2
Discovery Labware		151,833		143,244	6.0
-----					
TOTAL	\$	592,010	\$	549,943	7.6
-----					

TOTAL REVENUES	\$	3,754,302	\$	3,618,334	3.8
----------------	----	-----------	----	-----------	-----

</TABLE>

<TABLE>  
<CAPTION>

	FX Neutral % Growth	
	International	Total
<S>	<C>	<C>
MEDICAL SYSTEMS		
Medical Surgical	-	7.5
Consumer Health Care	1.4	(2.6)
Pharmaceutical Systems	17.0	17.5
Ophthalmic Systems	13.9	6.8
TOTAL	3.9	6.2
CLINICAL LABORATORY SOLUTIONS		
Preanalytical Solutions	5.9	12.8
Diagnostic Systems	6.5	3.1
TOTAL	6.2	7.8
BIOSCIENCES		
Immunocytometry & Reagents	23.3	11.8
Discovery Labware	6.5	9.1
TOTAL	18.9	11.1
TOTAL	6.6	7.4

</TABLE>